Newer therapies for vasculitis

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 3, 2009, Pages 379-389

  Hiemstra, Thomas F ^a   Jayne, David ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

alemtuzumab; clinical trials; etanercept; infliximab; intravenous immunoglobulin; leflunomide; mycophenolic acid; plasma exchange; rituximab; stem cell transplantation; therapy; tumour necrosis factor; vasculitis

Indexed keywords

15 DEOXYSPERGUALIN; ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; ATLIZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR;

ANAPHYLACTOID PURPURA; ANAPHYLAXIS; ANCA ASSOCIATED VASCULITIS; AORTA ARCH SYNDROME; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CHURG STRAUSS SYNDROME; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL TOXICITY; GIANT CELL ARTERITIS; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; LYMPHOCYTE DEPLETION; MENINGISM; MICROSCOPIC POLYANGIITIS; NEUTROPENIA; NONHUMAN; PEDIATRICS; PLASMAPHERESIS; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SERUM SICKNESS; UNSPECIFIED SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MYCOPHENOLIC ACID; PLASMA EXCHANGE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VASCULITIS;

EID: 66349116026     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.01.005     Document Type: Review

References (44)

1. Specks U., Fervenza F.C., McDonald T.J., and Hogan M.C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44 (2001) 2836
2. Walton E.W. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 2 (1958) 265
3. Jayne D., Rasmussen N., Andrassy K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349 (2003) 36
4. Booth A.D., Almond M.K., Burns A., et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41 (2003) 776
5. Booth A.D., Wallace S., McEniery C.M., et al. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum 50 (2004) 581
6. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 13 (2001) 48
7. Hoffman G.S., Leavitt R.Y., Kerr G.S., and Fauci A.S. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 35 (1992) 1322
8. de Groot K., Adu D., and Savage C.O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16 (2001) 2018
9. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 352 (2005) 351
10. Hellmich B., Flossmann O., Gross W.L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66 (2007) 605
11. Jayne D.R., Gaskin G., Rasmussen N., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18 (2007) 2180
12. Lockwood C.M., Pinching A.J., Sweny P., et al. Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. Lancet 1 (1977) 63
13. Booth A., Harper L., Hammad T., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15 (2004) 717
14. Mitoma H., Horiuchi T., Tsukamoto H., et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 58 (2008) 1248
15. Guillevin L., Jarrousse B., Lok C., et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 18 (1991) 567
16. Hu W., Liu C., Xie H., et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 23 (2008) 1307
17. Stassen P.M., Cohen Tervaert J.W., and Stegeman C.A. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 66 (2007) 798
18. Joy M.S., Hogan S.L., Jennette J.C., et al. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 20 (2005) 2725
19. Nowack R., Gobel U., Klooker P., et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10 (1999) 1965
20. Koukoulaki M., and Jayne D.R. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract 102 (2006) c100
21. Metzler C., Miehle N., Manger K., et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 46 (2007) 1087
22. Birck R., Newman M., Braun C., et al. 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis. Nephrol Dial Transplant 21 (2006) 58
23. Flossmann O., Baslund B., Bruchfeld A., et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis (2008)
24. Xiao H., Heeringa P., Hu P., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110 (2002) 955
25. de Lind van Wijngaarden R.A., Hauer H.A., Wolterbeek R., et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol 18 (2007) 2189
26. Specks U. Diffuse alveolar hemorrhage syndromes. Curr Opin Rheumatol 13 (2001) 12
27. Rossi F., Jayne D.R., Lockwood C.M., and Kazatchkine M.D. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 83 (1991) 298
28. Jayne D.R., Chapel H., Adu D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93 (2000) 433
29. Martinez V., Cohen P., Pagnoux C., et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 58 (2008) 308
30. Kotter I., Daikeler T., Amberger C., et al. Autologous stem cell transplantation of treatment-resistant systemic vasculitis-a single center experience and review of the literature. Clin Nephrol 64 (2005) 485
31. Kunitomi A., Ishikawa T., Tajima K., et al. Bone marrow transplantation with a reduced-intensity conditioning regimen in a patient with Wegener granulomatosis and therapy-related leukemia. Int J Hematol 83 (2006) 262
32. Booth A.D., Jefferson H.J., Ayliffe W., et al. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 61 (2002) 559
33. Josselin L., Mahr A., Cohen P., et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 67 (2008) 1343
34. Stone J.H., Holbrook J.T., Marriott M.A., et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 54 (2006) 1608
35. Walsh M., Chaudhry A., and Jayne D.R. Long-term follow-up of relapsing/refractory ANCA associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis (2007)
36. Schmitt W.H., Hagen E.C., Neumann I., et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 65 (2004) 1440
37. Voswinkel J., Mueller A., Kraemer J.A., et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 65 (2006) 859
38. Walsh M., and Jayne D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int 72 (2007) 676
39. Keogh K.A., Wylam M.E., Stone J.H., and Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52 (2005) 262
40. Smith K.G., Jones R.B., Burns S.M., and Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 54 (2006) 2970
41. Ng K.P., Cambridge G., Leandro M.J., et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 66 (2007) 1259
42. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572
43. Aries P.M., Hellmich B., Voswinkel J., et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65 (2006) 853
44. Dillon M.J., and Ozen S. A new international classification of childhood vasculitis. Pediatr Nephrol 21 (2006) 1219